Bold Therapeutics is pleased to be featured in Insights Magazine’s Fall Issue. The article: “Bold Therapeutics: Defeating Cancer Drug Resistance” highlights the incredible work we are doing in oncology, including our… Read More
Excited to announce the launch of www.herstasis.com, a free site with science-based information on perimenopause changes in women plus an overview of symptom treatments. Don’t know what that is, come… Read More
The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…. Read More
If you need to work with experts in a new field or identify rising stars, Baehl Innovation can help. Our team has years of experience in identifying experts and will… Read More
VANCOUVER, BC – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced… Read More
